SEASTAR MEDICAL HOLDING CORPORATION - COMMON STOCK

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

22 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

13 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

08 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

23 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

11 Dec 2024 05:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

04 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial

03 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

22 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

15 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

13 Nov 2024 16:05:22 By Nasdaq GlobeNewswire

FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial

01 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

31 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

25 Oct 2024 10:32:00 By Nasdaq GlobeNewswire

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

25 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial

23 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

22 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

18 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

15 Oct 2024 07:30:00 By Nasdaq GlobeNewswire